4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Angiosarcoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 111 ongoing clinical trials involving Angiosarcoma
Of the 111 trials,50 trials are in Phase II
Furthermore, 41 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Angiosarcoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Angiosarcoma, an Oncology indication. The highest number of ongoing clinical trials involving Angiosarcoma is in North America. Asia-Pacific and Europe are among some of the other prominent regions involved in Angiosarcoma-related drug trials.

Sun Yat-sen University: The leading ongoing Angiosarcoma -related clinical trials sponsor

Sun Yat-sen University, the China-based government institute, is the top sponsor for Angiosarcoma-related ongoing clinical trials.

Memorial Sloan Kettering Cancer Center, National Cancer Institute US, Centre Leon Berard, PhilogenSpA, and Antoni van Leeuwenhoek are a few other notable sponsors involving Angiosarcoma.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Angiosarcoma

Aldesleukin (Imunace), and Paclitaxel (Taxol) are among the key marketed drugs involving Angiosarcoma.

Aldesleukin (Imunace) consists of recombinant interleukin-2, is an immunoregulatory and antineoplastic product. It functions via the Interleukin 2 Receptor (IL2R) Agonist. It is formulated as a lyophilized powder for solution for intravenous administration. It is indicated for the treatment of angiosarcoma and kidney cancer. Aldesleukin was first approved in 1992 and is marketed globally including Japan by several prominent pharma giants including Kyowa CritiCare Co Ltd.

Paclitaxel (Taxol) is an anti-neoplastic agent. It functions via the Tubulin Inhibitor mechanism of action. It is formulated as a solution. It is formulated as an injectable concentrate solution for the intravenous route of administration. Taxol is indicated in the subsequent therapy for the treatment of advanced carcinoma of the ovary as well as the first-line therapy in combination with cisplatin and adjuvant therapy of node-positive breast cancer administered sequentially to standard doxorubicin containing combination chemotherapy. Paclitaxel was first approved in 1992 and is marketed globally including the US, France, Germany, China, and Japan by several prominent pharma giants including HQ Speciality Pharma.